Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?
about
The Algal Meroterpene 11-Hydroxy-1'-O-Methylamentadione Ameloriates Dextran Sulfate Sodium-Induced Colitis in MiceClinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.IBD LIVE Series-Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa.Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.Outcomes After Primary Infliximab Treatment Failure in Inflammatory Bowel Disease.
P2860
Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Use of a third anti-TNF after ...... bowel disease: is it worth it?
@en
type
label
Use of a third anti-TNF after ...... bowel disease: is it worth it?
@en
prefLabel
Use of a third anti-TNF after ...... bowel disease: is it worth it?
@en
P2860
P921
P1476
Use of a third anti-TNF after ...... bowel disease: is it worth it?
@en
P2860
P304
P356
10.3109/00365521.2014.928901
P577
2015-01-30T00:00:00Z